Exogenous human surfactant for treatment of severe respiratory distress syndrome: A randomized prospective clinical trial
We performed a randomized, prospective clinical trial comparing intratracheal administration of human surfactant with conventional treatment with intermittent mandatory mechanical ventilation alone for treatment of severe respiratory distress syndrome in preterm infants of 30 days was significantly...
Gespeichert in:
| Veröffentlicht in: | The Journal of pediatrics 1985-06, Vol.106 (6), p.963-969 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 969 |
|---|---|
| container_issue | 6 |
| container_start_page | 963 |
| container_title | The Journal of pediatrics |
| container_volume | 106 |
| creator | Hallman, Mikko Merritt, T. Allen Jarvenpaa, Anna-Liisa Boynton, Bruce Mannino, Frank Gluck, Louis Moore, Thomas Edwards, David |
| description | We performed a randomized, prospective clinical trial comparing intratracheal administration of human surfactant with conventional treatment with intermittent mandatory mechanical ventilation alone for treatment of severe respiratory distress syndrome in preterm infants of 30 days was significantly less in the surfactant group. This trial confirms the efficacy of treatment with human surfactant in preterm infants with severe respiratory distress syndrome. |
| doi_str_mv | 10.1016/S0022-3476(85)80253-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76121874</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022347685802535</els_id><sourcerecordid>76121874</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-de54636c5751be6120479027ea8e1d743b8df566788aeded614fe47a1d4fe38c3</originalsourceid><addsrcrecordid>eNqFkE1v1DAQhi1EVZaFn1DJB4TgkNaO4y8uVVWVD6lSD8DZ8toTMErixZOsWH49bne1V04ja555PfMQcsHZJWdcXX1lrG0b0Wn1zsj3hrVSNPIZWXFmdaOMEM_J6oS8IC8RfzHGbMfYOTkXxthW2hXZ3_3JP2DKC9Kfy-gnikvpfZj9NNM-FzoX8PMI9ZV7irCDArQAblPxcy57GhNWBJHifoolj_CB3tDip5jH9Bci3ZaMWwhz2gENQ5pS8EMNTX54Rc56PyC8PtY1-f7x7tvt5-b-4dOX25v7Jghj5yaC7JRQQWrJN6B4yzptWavBG-BRd2JjYi-V0sZ4iBAV73rotOexVmGCWJO3h9y6yu8FcHZjwgDD4CeoZztdM7mpQWsiD2CoO2OB3m1LGn3ZO87co3L3pNw9-nRGuiflTta5i-MHy2aEeJo6Oq79N8e-x3p9X-2EhCfMttZ2llfs-oBBlbFLUByGBFOAmEoV6GJO_1nkH-79oJg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76121874</pqid></control><display><type>article</type><title>Exogenous human surfactant for treatment of severe respiratory distress syndrome: A randomized prospective clinical trial</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Hallman, Mikko ; Merritt, T. Allen ; Jarvenpaa, Anna-Liisa ; Boynton, Bruce ; Mannino, Frank ; Gluck, Louis ; Moore, Thomas ; Edwards, David</creator><creatorcontrib>Hallman, Mikko ; Merritt, T. Allen ; Jarvenpaa, Anna-Liisa ; Boynton, Bruce ; Mannino, Frank ; Gluck, Louis ; Moore, Thomas ; Edwards, David</creatorcontrib><description>We performed a randomized, prospective clinical trial comparing intratracheal administration of human surfactant with conventional treatment with intermittent mandatory mechanical ventilation alone for treatment of severe respiratory distress syndrome in preterm infants of <30 weeks gestation. Twenty-two infants (mean gestational age 27.0 weeks, mean birth weight 987 gm) were given surfactant, and 23 infants (mean gestational age 27.2 week, mean birth weight 1055 gm) received intermittent mandatory ventilation. Infants given surfactant required less FiO
2 during the first week, had lower mean airway pressure during the first 48 hours, and had improved ventilatory index and a/A Po
2 ratio. Death or the occurrence of bronchopulmonary dysplasia was significantly less among infants given surfactant (P=0.019). Pneumothorax, pulmonary interstitial emphysema, and need for Fio
2≥0.3 for >30 days was significantly less in the surfactant group. This trial confirms the efficacy of treatment with human surfactant in preterm infants with severe respiratory distress syndrome.</description><identifier>ISSN: 0022-3476</identifier><identifier>EISSN: 1097-6833</identifier><identifier>DOI: 10.1016/S0022-3476(85)80253-5</identifier><identifier>PMID: 3889259</identifier><identifier>CODEN: JOPDAB</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Amniotic Fluid - analysis ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Birth Weight ; Clinical Trials as Topic ; Emergency and intensive care: neonates and children. Prematurity. Sudden death ; Female ; Humans ; Infant, Newborn ; Infant, Premature, Diseases - mortality ; Infant, Premature, Diseases - therapy ; Intensive care medicine ; Male ; Medical sciences ; Prospective Studies ; Random Allocation ; Respiratory Distress Syndrome, Newborn - mortality ; Respiratory Distress Syndrome, Newborn - therapy ; Surface-Active Agents - therapeutic use ; Time Factors</subject><ispartof>The Journal of pediatrics, 1985-06, Vol.106 (6), p.963-969</ispartof><rights>1985 The C. V. Mosby Company</rights><rights>1985 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-de54636c5751be6120479027ea8e1d743b8df566788aeded614fe47a1d4fe38c3</citedby><cites>FETCH-LOGICAL-c389t-de54636c5751be6120479027ea8e1d743b8df566788aeded614fe47a1d4fe38c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0022347685802535$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=9299491$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3889259$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hallman, Mikko</creatorcontrib><creatorcontrib>Merritt, T. Allen</creatorcontrib><creatorcontrib>Jarvenpaa, Anna-Liisa</creatorcontrib><creatorcontrib>Boynton, Bruce</creatorcontrib><creatorcontrib>Mannino, Frank</creatorcontrib><creatorcontrib>Gluck, Louis</creatorcontrib><creatorcontrib>Moore, Thomas</creatorcontrib><creatorcontrib>Edwards, David</creatorcontrib><title>Exogenous human surfactant for treatment of severe respiratory distress syndrome: A randomized prospective clinical trial</title><title>The Journal of pediatrics</title><addtitle>J Pediatr</addtitle><description>We performed a randomized, prospective clinical trial comparing intratracheal administration of human surfactant with conventional treatment with intermittent mandatory mechanical ventilation alone for treatment of severe respiratory distress syndrome in preterm infants of <30 weeks gestation. Twenty-two infants (mean gestational age 27.0 weeks, mean birth weight 987 gm) were given surfactant, and 23 infants (mean gestational age 27.2 week, mean birth weight 1055 gm) received intermittent mandatory ventilation. Infants given surfactant required less FiO
2 during the first week, had lower mean airway pressure during the first 48 hours, and had improved ventilatory index and a/A Po
2 ratio. Death or the occurrence of bronchopulmonary dysplasia was significantly less among infants given surfactant (P=0.019). Pneumothorax, pulmonary interstitial emphysema, and need for Fio
2≥0.3 for >30 days was significantly less in the surfactant group. This trial confirms the efficacy of treatment with human surfactant in preterm infants with severe respiratory distress syndrome.</description><subject>Amniotic Fluid - analysis</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Birth Weight</subject><subject>Clinical Trials as Topic</subject><subject>Emergency and intensive care: neonates and children. Prematurity. Sudden death</subject><subject>Female</subject><subject>Humans</subject><subject>Infant, Newborn</subject><subject>Infant, Premature, Diseases - mortality</subject><subject>Infant, Premature, Diseases - therapy</subject><subject>Intensive care medicine</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Prospective Studies</subject><subject>Random Allocation</subject><subject>Respiratory Distress Syndrome, Newborn - mortality</subject><subject>Respiratory Distress Syndrome, Newborn - therapy</subject><subject>Surface-Active Agents - therapeutic use</subject><subject>Time Factors</subject><issn>0022-3476</issn><issn>1097-6833</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1985</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1v1DAQhi1EVZaFn1DJB4TgkNaO4y8uVVWVD6lSD8DZ8toTMErixZOsWH49bne1V04ja555PfMQcsHZJWdcXX1lrG0b0Wn1zsj3hrVSNPIZWXFmdaOMEM_J6oS8IC8RfzHGbMfYOTkXxthW2hXZ3_3JP2DKC9Kfy-gnikvpfZj9NNM-FzoX8PMI9ZV7irCDArQAblPxcy57GhNWBJHifoolj_CB3tDip5jH9Bci3ZaMWwhz2gENQ5pS8EMNTX54Rc56PyC8PtY1-f7x7tvt5-b-4dOX25v7Jghj5yaC7JRQQWrJN6B4yzptWavBG-BRd2JjYi-V0sZ4iBAV73rotOexVmGCWJO3h9y6yu8FcHZjwgDD4CeoZztdM7mpQWsiD2CoO2OB3m1LGn3ZO87co3L3pNw9-nRGuiflTta5i-MHy2aEeJo6Oq79N8e-x3p9X-2EhCfMttZ2llfs-oBBlbFLUByGBFOAmEoV6GJO_1nkH-79oJg</recordid><startdate>198506</startdate><enddate>198506</enddate><creator>Hallman, Mikko</creator><creator>Merritt, T. Allen</creator><creator>Jarvenpaa, Anna-Liisa</creator><creator>Boynton, Bruce</creator><creator>Mannino, Frank</creator><creator>Gluck, Louis</creator><creator>Moore, Thomas</creator><creator>Edwards, David</creator><general>Mosby, Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198506</creationdate><title>Exogenous human surfactant for treatment of severe respiratory distress syndrome: A randomized prospective clinical trial</title><author>Hallman, Mikko ; Merritt, T. Allen ; Jarvenpaa, Anna-Liisa ; Boynton, Bruce ; Mannino, Frank ; Gluck, Louis ; Moore, Thomas ; Edwards, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-de54636c5751be6120479027ea8e1d743b8df566788aeded614fe47a1d4fe38c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1985</creationdate><topic>Amniotic Fluid - analysis</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Birth Weight</topic><topic>Clinical Trials as Topic</topic><topic>Emergency and intensive care: neonates and children. Prematurity. Sudden death</topic><topic>Female</topic><topic>Humans</topic><topic>Infant, Newborn</topic><topic>Infant, Premature, Diseases - mortality</topic><topic>Infant, Premature, Diseases - therapy</topic><topic>Intensive care medicine</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Prospective Studies</topic><topic>Random Allocation</topic><topic>Respiratory Distress Syndrome, Newborn - mortality</topic><topic>Respiratory Distress Syndrome, Newborn - therapy</topic><topic>Surface-Active Agents - therapeutic use</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hallman, Mikko</creatorcontrib><creatorcontrib>Merritt, T. Allen</creatorcontrib><creatorcontrib>Jarvenpaa, Anna-Liisa</creatorcontrib><creatorcontrib>Boynton, Bruce</creatorcontrib><creatorcontrib>Mannino, Frank</creatorcontrib><creatorcontrib>Gluck, Louis</creatorcontrib><creatorcontrib>Moore, Thomas</creatorcontrib><creatorcontrib>Edwards, David</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of pediatrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hallman, Mikko</au><au>Merritt, T. Allen</au><au>Jarvenpaa, Anna-Liisa</au><au>Boynton, Bruce</au><au>Mannino, Frank</au><au>Gluck, Louis</au><au>Moore, Thomas</au><au>Edwards, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Exogenous human surfactant for treatment of severe respiratory distress syndrome: A randomized prospective clinical trial</atitle><jtitle>The Journal of pediatrics</jtitle><addtitle>J Pediatr</addtitle><date>1985-06</date><risdate>1985</risdate><volume>106</volume><issue>6</issue><spage>963</spage><epage>969</epage><pages>963-969</pages><issn>0022-3476</issn><eissn>1097-6833</eissn><coden>JOPDAB</coden><abstract>We performed a randomized, prospective clinical trial comparing intratracheal administration of human surfactant with conventional treatment with intermittent mandatory mechanical ventilation alone for treatment of severe respiratory distress syndrome in preterm infants of <30 weeks gestation. Twenty-two infants (mean gestational age 27.0 weeks, mean birth weight 987 gm) were given surfactant, and 23 infants (mean gestational age 27.2 week, mean birth weight 1055 gm) received intermittent mandatory ventilation. Infants given surfactant required less FiO
2 during the first week, had lower mean airway pressure during the first 48 hours, and had improved ventilatory index and a/A Po
2 ratio. Death or the occurrence of bronchopulmonary dysplasia was significantly less among infants given surfactant (P=0.019). Pneumothorax, pulmonary interstitial emphysema, and need for Fio
2≥0.3 for >30 days was significantly less in the surfactant group. This trial confirms the efficacy of treatment with human surfactant in preterm infants with severe respiratory distress syndrome.</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>3889259</pmid><doi>10.1016/S0022-3476(85)80253-5</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-3476 |
| ispartof | The Journal of pediatrics, 1985-06, Vol.106 (6), p.963-969 |
| issn | 0022-3476 1097-6833 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76121874 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Amniotic Fluid - analysis Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Birth Weight Clinical Trials as Topic Emergency and intensive care: neonates and children. Prematurity. Sudden death Female Humans Infant, Newborn Infant, Premature, Diseases - mortality Infant, Premature, Diseases - therapy Intensive care medicine Male Medical sciences Prospective Studies Random Allocation Respiratory Distress Syndrome, Newborn - mortality Respiratory Distress Syndrome, Newborn - therapy Surface-Active Agents - therapeutic use Time Factors |
| title | Exogenous human surfactant for treatment of severe respiratory distress syndrome: A randomized prospective clinical trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T01%3A04%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Exogenous%20human%20surfactant%20for%20treatment%20of%20severe%20respiratory%20distress%20syndrome:%20A%20randomized%20prospective%20clinical%20trial&rft.jtitle=The%20Journal%20of%20pediatrics&rft.au=Hallman,%20Mikko&rft.date=1985-06&rft.volume=106&rft.issue=6&rft.spage=963&rft.epage=969&rft.pages=963-969&rft.issn=0022-3476&rft.eissn=1097-6833&rft.coden=JOPDAB&rft_id=info:doi/10.1016/S0022-3476(85)80253-5&rft_dat=%3Cproquest_cross%3E76121874%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76121874&rft_id=info:pmid/3889259&rft_els_id=S0022347685802535&rfr_iscdi=true |